LAS VEGAS, Oct. 22, 2024
JAK inhibitors are a class of medications that work by blocking Janus kinases (JAKs), enzymes that are involved in the signaling pathways of various cytokines and growth factors. JAK inhibitors offer a more targeted approach to treating immune-mediated diseases compared to traditional therapies like corticosteroids or conventional immunosuppressants; this specificity reduces side effects and increases efficacy and is a major driver for the demand for JAK inhibitors.
Advertisement
LAS VEGAS, Oct. 22, 2024 /PRNewswire/ -- DelveInsight's 'JAK Inhibitors Pipeline Insight 2024' report provides comprehensive global coverage of pipeline JAK inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the JAK inhibitors pipeline domain.
Advertisement
Key Takeaways from the JAK Inhibitors Pipeline Report
Request a sample and discover the recent advances in JAK inhibitors drugs @ JAK Inhibitors Pipeline Report
The JAK inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage JAK inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the JAK inhibitors clinical trial landscape.
JAK Inhibitors Overview
Janus kinase (JAK) inhibitors are a class of medications designed to interfere with the activity of the Janus kinase family of enzymes, which play a crucial role in the signaling pathways of immune responses. These enzymes are key mediators in transmitting signals from cytokines and growth factors, which regulate blood cell production and immune system function. By blocking these signals, JAK inhibitors help to control the overactive immune response seen in several inflammatory and autoimmune diseases. They have shown significant efficacy in treating conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, among others. The most common JAK inhibitors include tofacitinib, baricitinib, and upadacitinib, which are administered orally.
Beyond their role in autoimmune diseases, JAK inhibitors are also being explored for use in treating certain cancers and myeloproliferative disorders, where abnormal JAK signaling contributes to uncontrolled cell growth. In diseases like myelofibrosis and polycythemia vera, JAK inhibitors can help reduce symptoms and improve quality of life. However, there are potential side effects associated with their use, including increased susceptibility to infections, blood clots, and cardiovascular risks, given their impact on the immune system. As research continues, the therapeutic potential of JAK inhibitors is expanding, offering new hope for patients with difficult-to-treat conditions.
Find out more about JAK inhibitors drugs @ JAK Inhibitors Analysis
A snapshot of the Pipeline JAK Inhibitors Drugs mentioned in the report:
Drugs
Company
Phase
Indication
RoA
Povorcitinib
Incyte Corporation
Phase III
Hidradenitis suppurativa; Vitiligo
Oral
Ritlecitinib
Pfizer
Phase III
Ulcerative colitis; Vitiligo
Oral
CPL409116
Celon Pharma
Phase II
Rheumatoid arthritis
Oral
ATI-2138
Aclaris Therapeutics
Phase II
Atopic dermatitis
Oral
Golidocitinib
Dizal Pharmaceutical
Phase II
Non-small cell lung cancer
Oral
AJ1–11095,
Ajax Therapeutics, Inc.
Phase I
Primary Myelofibrosis
Oral
SDC 1802
Sareum
Preclinical
Precursor T-cell lymphoblastic leukaemia-lymphoma
Oral
Learn more about the emerging JAK inhibitors @ JAK Inhibitors Clinical Trials
JAK Inhibitors Therapeutics Assessment
The JAK inhibitors pipeline report proffers an integral view of the emerging JAK inhibitors segmented by stage, product type, molecule type, and route of administration.
Scope of the JAK Inhibitors Pipeline Report
Dive deep into rich insights for new JAK inhibitors, visit @ JAK Inhibitors Drugs
Table of Contents
1.
JAK Inhibitors Pipeline Report Introduction
2.
JAK Inhibitors Pipeline Report Executive Summary
3.
JAK Inhibitors Pipeline: Overview
4.
Analytical Perspective In-depth Commercial Assessment
5.
JAK Inhibitors Clinical Trial Therapeutics
6.
JAK Inhibitors Pipeline: Late-Stage Products (Pre-registration)
7.
JAK Inhibitors Pipeline: Late-Stage Products (Phase III)
8.
JAK Inhibitors Pipeline: Mid-Stage Products (Phase II)
9.
JAK Inhibitors Pipeline: Early-Stage Products (Phase I)
10.
JAK Inhibitors Pipeline Therapeutics Assessment
11.
Inactive Products in the JAK Inhibitors Pipeline
12.
Company-University Collaborations (Licensing/Partnering) Analysis
13.
Key Companies
14.
Key Products in the JAK Inhibitors Pipeline
15.
Unmet Needs
16.
Market Drivers and Barriers
17.
Future Perspectives and Conclusion
18.
Analyst Views
19.
Appendix
For further information on the JAK inhibitors pipeline therapeutics, reach out @ JAK Inhibitors Therapeutics
Related Reports
JAK Inhibitors Market
JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Eli Lilly and Company, Suzhou Zelgen Biopharmaceuticals Co., Ltd, Incyte Corporation, Kartos Therapeutics, Inc., Dompé Farmaceutici S.p.A, Sanofi, Kiniksa Pharmaceuticals, Ltd., Celgene, Abivax S.A., Telios Pharma, Inc., AstraZeneca, Karyopharm Therapeutics Inc, TWi Biotechnology, Inc., Geron Corporation, Ajax Therapeutics, Inc., among others.
JAK Inhibitors Competitive Landscape
JAK Inhibitors Competitive Landscape – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.
KRAS Inhibitors Market
KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, among others.
PD/L-1 Inhibitors Market
PD/L-1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD/L-1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti [email protected]+14699457679
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/jak-inhibitors-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a-diverse-pipeline-comprising-50-companies-working-in-the-domain-302282576.html
SOURCE DelveInsight Business Research, LLP
